Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$8.99 USD
-0.17 (-1.86%)
Updated May 28, 2024 04:00 PM ET
After-Market: $9.00 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RXRX 8.99 -0.17(-1.86%)
Will RXRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXRX
Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know
Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know
Other News for RXRX
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
AlphaFold 3: The Future Of AI In Biotechnology Is Here
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
Jim Cramer Offers His Take On Corning, Calls This Healthcare Stock A 'Terrific Spec'
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In